Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
|
AUXILIUM PHARMACEUTICALS INC (AUXL)
|
Add to portfolio |
|
|
|
| Price: |
$17.22
| | Metrics |
| OS: |
51.0
|
M
| |
-101
|
% ROE
|
| Market cap: |
$879
|
M
| |
-76
|
% ROIC
|
|
Net debt:
|
$520
|
M
| |
7.2
|
x Debt/EBITDA
|
|
EV:
|
$1.4
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$72.1
|
M
| |
19.4
|
x EV/EBITDA
|
|
EBIT
|
($94.7)
|
M
| |
|
|
| EPS |
($3.27)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 |
| Revenues | 400.7 | 395.3 | 264.3 | 211.4 | 164.0 | 125.4 | 95.7 | 68.5 |
| Revenue growth | 1.4% | 49.5% | 25.0% | 28.9% | 30.8% | 31.0% | 39.8% | 60.0% |
| Cost of goods sold | 112.0 | 78.3 | 55.7 | 49.7 | 37.1 | 29.5 | 24.6 | 17.7 |
| Gross profit | 288.7 | 316.9 | 208.7 | 161.7 | 127.0 | 95.9 | 71.1 | 50.8 |
| Gross margin | 72.0% | 80.2% | 78.9% | 76.5% | 77.4% | 76.5% | 74.3% | 74.2% |
| Selling, general and administrative | 250.2 | 185.5 | 179.9 | 164.7 | 129.2 | 89.5 | 72.8 | 61.3 |
| Research and development | 50.2 | 45.9 | 61.9 | 48.0 | 51.4 | 54.5 | 42.8 | 37.9 |
| EBITA | -23.1 | 85.5 | -33.2 | -51.0 | -53.6 | -48.1 | -44.4 | -48.4 |
| EBITA margin | -5.8% | 21.6% | -12.6% | -24.1% | -32.7% | -38.4% | -46.4% | -70.6% |
| Amortization of intangibles | 45.0 | | | | | | | |
| EBIT | -68.1 | 85.5 | -33.2 | -51.0 | -53.6 | -48.1 | -44.4 | -48.4 |
| EBIT margin | -17.0% | 21.6% | -12.6% | -24.1% | -32.7% | -38.4% | -46.4% | -70.6% |
| Pre-tax income | -96.4 | 85.9 | -32.9 | 0.0 | -53.5 | -46.3 | -40.7 | -45.9 |
| Income taxes | -78.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 81.3% | 0.0% | 0.0% | | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -18.1 | 85.9 | -32.9 | -51.2 | -53.5 | -46.3 | -40.7 | -45.9 |
| Net margin | -4.5% | 21.7% | -12.5% | -24.2% | -32.6% | -36.9% | -42.5% | -67.1% |
| |
| Diluted EPS | ($0.37) | $1.74 | ($0.69) | ($1.08) | ($1.22) | ($1.12) | ($1.07) | ($1.48) |
| Shares outstanding (diluted) | 49.3 | 49.3 | 47.9 | 47.4 | 43.8 | 41.3 | 38.2 | 31.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|